CorMedix, Inc. (CRMD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.43-0.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRMD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain and increase full-year 2026 consolidated revenue guidance to $325-$345 million.
Stated as a priority in 3 of last 3 quarters. Full-year 2026 revenue guidance was initially set at $300-$320 million in 2025-Q4, then increased to $325-$345 million by 2026-Q1 and maintained at that level in 2026-Q2. Revenue grew from $39.1 million in 2025-Q1 to $127.4 million in 2026-Q1 and $101.9 million in 2026-Q2, supporting the raised guidance. The trajectory matches management's stated priority, delivering growth and maintaining guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company maintains full-year 2026 consolidated revenue guidance of $325 to $345 million”
“The Company increases full-year 2026 net revenue guidance to a range of $325 to $345 million”
“CorMedix reiterates previously established guidance for 2026, including net revenue of between $300 and $320 million”
Raise and maintain full-year adjusted EBITDA guidance for 2026 to $125-$140 million.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA guidance was initially $100-$125 million in 2025-Q4, increased to $115-$135 million in 2026-Q1, and further raised to $125-$140 million in 2026-Q2. Adjusted EBITDA grew from $22.4 million in 2025-Q2 to $58.7 million in 2026-Q2, showing delivery on profitability targets. The trajectory aligns with management's raised guidance and focus on profitability.
“The Company raises full-year adjusted EBITDA guidance to a range of $125 to $140 million”
“The Company increases full-year adjusted EBITDA guidance to a range of $115 to $135 million”
“CorMedix reiterates previously established guidance for 2026, including adjusted EBITDA of between $100 and $125 million”
Progress REZZAYO Phase III clinical trial and prepare FDA supplemental NDA submission for prophylaxis indication.
Stated as a priority in 3 disclosures including 2026-Q1 and 2026-Q2 and an April 2026 press release. The company announced positive Phase III topline results for REZZAYO prophylaxis in April 2026 and anticipates FDA sNDA submission in Q3 2026 with potential agency action in H1 2027. This reflects progress in clinical development and regulatory preparation, consistent with management's stated priority.
“The company anticipates FDA submission of the sNDA for an expanded indication of REZZAYO for prophylaxis in Q3 2026”
“CorMedix is actively working to prepare for FDA submission of the sNDA, expected in the second half of 2026”
Defend intellectual property rights for MINOCIN against generic infringement challenges.
Newly stated in 2026-Q2 via a June 8, 2026 press release. The Federal Circuit affirmed a district court ruling that Nexus Pharmaceuticals infringed CorMedix's MINOCIN patents, reinforcing the company's commitment to protect its intellectual property. This legal victory supports management's stated priority to defend its patent portfolio.
Sign multi-year supply agreements with top dialysis providers to increase DefenCath utilization.
Newly stated in 2026-Q2. The company announced a multi-year supply agreement for DefenCath with a Large Dialysis Operator, expanding its commercial contract footprint to include all top 5 U.S. dialysis providers. This represents progress in commercial expansion consistent with management's growth priorities.
“Signed new multi-year commercial supply agreement for DefenCath with a Large Dialysis Operator, covering all top 5 providers”
Over the trailing year it converted 1.13x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
10 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.